<table border="1" id="id_e1ef4876-76ca-4537-9aa8-5ef13ca79772" width="230.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_5ae953ef-4421-44c7-85ab-94ac72162983">Table 2: Dose to body weight range to achieve similar steady-state exposure (AUC<sub>0-24hr</sub>) to unbound oxaprozin in JRA patients relative to 70 kg adult rheumatoid arthritis patients administered oxaprozin 1200 mg QD<footnote id="id-d4ca30e8-3166-4ede-b19d-9821ecc10fc7">Model-based nomogram derived from unbound oxaprozin steady-state drug plasma concentrations of JRA patients weighing 22.1 to 42.7 kg or ≥ 45.0 kg administered oxaprozin 600 mg or 1200 mg QD for 14 days, respectively.</footnote>
</caption>
<col width="37.0%"></col>
<col width="63.0%"></col>
<tbody>
<tr id="id_6067a2eb-1f9c-47e9-876a-d997e2a38a4d">
<td align="center" stylecode="Toprule Botrule Lrule" valign="middle">Dose (mg)</td>
<td align="center" stylecode="Botrule Rrule" valign="middle">Body Weight Range (kg)</td>
</tr>
<tr id="id_27756a65-6d7e-4eb9-9316-cf5c8f338266">
<td align="center" stylecode="Lrule Botrule" valign="middle">600</td>
<td align="center" stylecode="Botrule Rrule" valign="middle">22 to 31</td>
</tr>
<tr id="id_073fe6a3-0cd8-4995-a45e-d718755ec115">
<td align="center" stylecode="Lrule Botrule" valign="middle">900</td>
<td align="center" stylecode="Botrule Rrule" valign="middle">32 to 54</td>
</tr>
<tr id="id_ae20dcfa-7401-4726-882b-3d3c57bbf5ba">
<td align="center" stylecode="Lrule Botrule" valign="middle">1200</td>
<td align="center" stylecode="Botrule Rrule" valign="middle">≥ 55</td>
</tr>
</tbody>
</table>